-
2 days ago | 
flipboard.com | Karen Gilchrist
3 hours ago40 of the best AI courses you can take online for freeFind a wide range of free online courses on everything from ChatGPT to Copilot. TL;DR: A wide range of AI courses are available to take for free on Udemy. We all know by now that there is a small chance that AI is going to take over the world.
-
2 days ago | 
cnbc.com | Karen Gilchrist
An Equestrian Knight Device logo on a flag outside the Burberry Group Plc luxury boutique in London, UK, on Tuesday, May 13, 2025. Bloomberg | Getty ImagesBurberry on Wednesday announced a slew of organizational changes, amid continued turnaround efforts at the embattled luxury house. The company said the measures could lead to a "reduction in people-related costs which could impact around 1,700 roles globally" over the lifetime of the program, set to complete in 2027.
-
1 week ago | 
cnbc.com | Karen Gilchrist
A Puma sportswear store in central London, UK, on Thursday, May 1, 2025. Bloomberg | Getty ImagesHousehold brands including Pandora, Puma and Hugo Boss all said this week that they are evaluating their pricing strategies in the U.S. and beyond in the event that President Donald Trump's most punitive levies come into effect. Some others, meanwhile, said that they are altering their supply chains and potentially revising their sales forecasts amid U.S. trade policy uncertainty.
-
1 week ago | 
cnbc.com | Karen Gilchrist
CNBC's Karen Gilchrist discusses the initial impact of tariffs on Europe's consumer goods firms.
-
1 week ago | 
cnbc.com | Karen Gilchrist
A charm bracelet on display in a Pandora store in Copenhagen, Denmark. Danish jewelry brand Pandora has warned of significant price increases across the affordable jewelry industry if U.S. President Donald Trump's proposed tariff hikes come into play following the White House's 90-day pause on the levies announced in April.
-
1 week ago | 
cnbc.com | Karen Gilchrist
Flags with the logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy are pictures while the company presents the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025. Mads Claus Rasmussen | Afp | Getty ImagesNovo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast amid weaker sales of its blockbuster Wegovy weight loss drugs.
-
1 week ago | 
nbcchicago.com | Karen Gilchrist
• Shares of Novo Nordisk climbed on Wednesday after it said that sales of its blockbuster Wegovy weight loss drug were seen improving in the second half of the year as copycat compounded drugs are phased out. • The Danish pharmaceutical giant reported lower-than-expected first-quarter sales of its flagship obesity drug and lowered its full-year sales growth forecast• For 2025, the company now sees sales growth of 13% to 21% at constant exchange rates, below the 16% to 24% previously forecast.
-
1 week ago | 
nbcwashington.com | Karen Gilchrist
Bloomberg | Getty Images Shares of Hugo Boss climbed after posting a lower-than-feared decline in first-quarter sales and reiterated its full-year guidance despite macroeconomic and tariff uncertainty. The high-end German retailer said revenues fell 2% on a currency adjusted basis to 999 million euros ($1.13 billion), slightly ahead of the 979 million euros forecast by analysts.
-
2 weeks ago | 
cnbc.com | Karen Gilchrist
COPENHAGEN, Denmark — The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish biotech Zealand Pharma's "next generation" weight loss candidate. The deal, announced in March and set to close in the second quarter, marks the Swiss pharma's latest bid to compete with weight loss heavyweights Novo Nordisk and Eli Lilly , after building out its obesity treatment portfolio over recent years.
-
2 weeks ago | 
cnbc.com | Karen Gilchrist
General view of the Swiss pharmaceutical and drug company Novartis AG headquarters on April 11, 2025 in Basel, Switzerland. Swiss pharmaceutical firm Novartis on Tuesday reported better-than-expected first-quarter sales and raised its full-year guidance. Net sales were up 15% on a constant currency basis to $13.2 billion, compared to the $13.12 billion estimated by analysts in an LSEG poll. Quarterly adjusted core operating income rose 27% to $5.58 billion versus the $5.07 billion expected.
